An interventional study of 0.1% Ropivacaine in Labor Pain, sponsored by General Hospital of Ningxia Medical University. Not yet recruiting. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by General Hospital of Ningxia Medical University · Not applicable, Interventional, and Treatment
This study aims to determine the 90% effective initial volume of 0.1% ropivacaine for labor analgesia under the double dural puncture epidural technique
Epidural labor analgesia is a widely adopted pain management modality for parturition. Recent technical advances including the dural puncture epidural (DPE) technique have considerably improved the quality of the childbirth experience. The double dural puncture epidural technique appears to improve this effect more effectively. This study aims to determine the 90% effective dose (ED₉₀) of an initial regimen of 0.1% ropivacaine, administered via the double dural puncture epidural technique for epidural labor analgesia.
410 studies on the registry are indexed under Labor Pain; 69 are open to participants now.
This study's planned enrollment of 30 is below the median of 100 across 336 interventional studies indexed under Labor Pain.
Browse Labor Pain studies →General Hospital of Ningxia Medical University is the lead sponsor of 108 studies on the registry; 42 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Labor analgesia via double dural puncture epidural technique
Drug: 0.1% Ropivacaine
An initial bolus of 0.1% ropivacaine , with a total volume of 10 mL (containing 10 mg ropivacaine), was administered to the first patient. For subsequent patients, the dose was adjusted in increments or decrements of 2 mL (2 mg 0.1% ropivacaine), based on whether a visual analogue scale pain score of less than 3 was achieved within 30 minutes after administration.
The ED₉₀ of ropivacaine
The ED₉₀ of ropivacaine required for parturients to achieve an numerical rating scale (NRS) pain score \<3 within 30 minutes following the initial administration.
Time frame: When the fetus is delivered
Visual analogue scale pain score
0-10; 0 = no pain, 10 = unbearable pain
Time frame: 10, 20, and 30 minutes after initial administration
Bromage score
0: full flexion of knees and ankles; 1: partial knee flexion with full ankle flexion; 2: inability to flex knees with partial ankle flexion; 3: inability to flex knees or ankles
Time frame: 30, 60, 120, 180, and 240 minutes after initial administration
APGAR score
A= Appearance P=Pulse G=Grimace A=Attitude R=Respiration
Time frame: 1 minute after delivery
APGAR score
A= Appearance P=Pulse G=Grimace A=Attitude R=Respiration
Time frame: 5 minutes after delivery
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jun 2027; primary completion for Jun 2027, 0 months later.
Of 183 non-industry interventional studies with no phase under Labor Pain, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's planned 0 months is below that.
Counting every sponsor, half of 185 studies reached it within 9 months; a quarter within 5 and three quarters within 14.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ropivacaine
General Hospital of Ningxia Medical University →